Forte Biosciences, Inc. — Director's Dealing 2017

Apr 12, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Tocagen Inc (TOCA)
CIK: 0001419041
Period of Report: 2017-04-12

Reporting Person: Jolly Douglas (EVP, Research & Pharm Devel)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	391304	Direct
Common Stock	21739	Indirect
Common Stock	21739	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$3.94	2023-03-13	Common Stock (57971)		Direct
Employee Stock Option (right to buy)	$14.98	2026-06-09	Common Stock (14492)		Direct

Footnotes

F1: The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F2: The stock option is fully vested.

F3: 1/4th of the shares vest one year after 4/1/2016; 1/48th of the shares vest monthly thereafter over the next 3 years.